Tucatinib promotes immune activation and synergizes with programmed cell death–1 and programmed cell death–ligand 1 inhibition in HER2-positive breast cancer

Abstract Background Programmed cell death–1 (PD-1) and programmed cell death–ligand 1 (PD-L1) inhibitors have poor efficacy in patients with trastuzumab-resistant advanced HER2-positive breast cancer. Tucatinib is a potent, selective anti-HER2 tyrosine kinase inhibitor with proven clinical benefit i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 2023-07, Vol.115 (7), p.805-814
Hauptverfasser:	Li, Ran, Sant, Sneha, Brown, Emmaline, Caramia, Franco, Nikolic, Bronte, Clarke, Kylie, Byrne, Ann, Lara Gonzalez, Luis E, Savas, Peter, Luen, Stephen J, Teo, Zhi Ling, Virassamy, Balaji, Neeson, Paul J, Darcy, Phillip K, Loi, Sherene
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal models Animals Antitumor activity Apoptosis B7-H1 Antigen Breast cancer Breast Neoplasms - pathology CD8 antigen CD8-Positive T-Lymphocytes Cell death Cell proliferation Dendritic cells Effectiveness Effector cells ErbB-2 protein Female Flow cytometry Gene expression Humans Immune response Immune system Immunological memory Inhibitors Investigations Kinases Ligands Lymphocytes Lymphocytes T Macrophages Major histocompatibility complex Memory cells Mice Monocytes Mortality Natural killer cells Patients PD-1 protein PD-L1 protein Programmed Cell Death 1 Receptor Receptor, ErbB-2 - metabolism Statistical analysis Suppressor cells Trastuzumab - therapeutic use Tumor Microenvironment Tumor-infiltrating lymphocytes Tumors Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!